Since Treg cell–mediated immunosuppression is generally deemed one of the main hurdles for cancer immunotherapy, various approaches for depletion and/or modulation of Treg cells (cyclophosphamide, denileukin diftitox, anti-CD25 antibody (daclizumab), anti-CD25 immunotoxin) have been characterized and tested with different clinical outcome. Here, IL2RA is linked to cancer.